

Author's Reply

To the Editor: I thank González Aragonese and Rami-Porta and colleagues for writing about our earlier letter on the treatment of stage cIIIA (cN2) bronchogenic carcinoma (prior to thoracotomy).¹ Both letters make relevant points that I agree with in general terms. In my opinion:

1. Although Rami-Porta and co-authors point out that there is no randomized trial that supports these recommendations, in order to recommend some patients for surgery following induction therapy of cN2 confirmed by cytology and histology, not only is it necessary to ensure that a cyN0 situation exists but also that pneumonectomy is not required.

2. Postoperative (adjuvant) chemotherapy following complete resection may be offered to patients with bronchogenic carcinoma in its initial

stages (<http://mbeneumologia.org/pautaCB>), as proposed by González Aragonese, although this is not currently considered as recommended treatment in cN2 (preoperative staging confirmed by cytology and histology).

Ángel López Encuentra

Servicio de Neumología,
Hospital Universitario 12 de Octubre,
Madrid, Spain.

1. López Encuentra A, Martín de Nicolás JL, Paz-Ares L, Bartolomé A y el Grupo Cooperativo de Carcinoma Broncogénico del Hospital Universitario 12 de Octubre de Madrid. Tratamiento multimodal en el carcinoma broncogénico no microcítico (N2) clínico: ¿cuál es la respuesta? Arch Bronconeumol. 2006;42:154.